NCT Number: NCT00362492
Safety Study of Stopping Thromboprophylaxis Based on Ultrasound Results After Total Knee Replacement
The purpose of this study is to determine whether stopping Low Molecular Weight Heparin (LMWH) thromboprophylaxis is safe after total knee joint replacement. The investigators select patients without proximal thromboembolism assessed by bilateral venous ultrasound examination 7-10 days after surgery. the investigators hypothesis is that stopping thromboprophylaxis is equally effective than prolonging thromboprophylaxis in order to prevent post-surgery complications in this population.
Looking for future studies?
Notify MeKey information
Conditions
Age range
46 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Hospital Alençon, Alençon, France
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- First total knee joint replacement
- Signed informed consent
Non-inclusion Criteria:
- History of venous thromboembolism/major bleeding/Heparin induced thrombopenia
- Active cancer
- Long-term anticoagulation
Treatment and study plan
Primary outcomes
-
Thromboembolism occuring between day 7-35 ;
-
Major bleeding occuring between day 7-35 ;
-
LMWH induced thrombopenia
-
All cause mortality
Sponsors and collaborators
Lead sponsor
University Hospital, Caen
Other
Registry information
Official study title
9-10 Days Versus Prolonged Thromboprophylaxis in Patients Without Evidence of Ultrasound Proximal Thromboembolism After Total Knee Joint Replacement: a Randomized Controlled Trial
Important dates
- Study start
- 2004
- Study completion
- 2007
- First posted
- Aug 10, 2006
- Registry last updated
- Oct 28, 2010
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Thromboembolic Risk Screening in Patients With Cancer and COVID-19
NCT04616846
COVID-19, Cardiovascular Diseases
Cagnes-sur-Mer, Alpes-Maritimes, France
View Trial DetailsA Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
NCT05643885
Cardiovascular Diseases, Embolism and Thrombosis
New York, United States
View Trial DetailsLow Molecular Weight Heparin or no Treatment Following Cesarean Delivery
NCT06118957
Cardiovascular Diseases, Embolism and Thrombosis
Salt Lake City, Utah, United States
View Trial DetailsTINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
NCT05625932
Cardiovascular Diseases, Colonic Diseases
Santiago de Compostela, A Coruña, Spain
View Trial Details